Literature DB >> 35181798

Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) for the detection of muscle-invasive bladder cancer: a meta-analysis.

Yuebo Feng1, Kai Zhong1, Rui Chen1, Weibin Zhou2.   

Abstract

PURPOSE: Vesical Imaging-Reporting and Data System (VI-RADS) was proposed and considered as a standardized reporting criterion for bladder magnetic resonance imaging (MRI). VI-RADS could suggest the likelihood of muscle invasion based on the multiparametric MRI (mp-MRI) findings which contain five-point scores. The current study is designed to comprehensively and systematically evaluate the diagnostic performance of VI-RADS (score 3 and 4) for predicting muscle invasion.
METHODS: The Cochrane Library, Embase, and PubMed were searched comprehensively from inception to October 2021.
RESULTS: Finally, 19 studies incorporating 2900 patients were enrolled. The pooled sensitivity and specificity of VI-RADS 3 for predicting muscle invasion were 0.92 (95%CI 0.89-0.94) and 0.82 (95%CI 0.76-0.87), respectively. The pooled sensitivity and specificity of VI-RADS 4 were 0.78 (95%CI 0.72-0.83) and 0.96 (95%CI 0.93-0.97), respectively. And the area under the curve (AUCs) of VI-RADS 3 and 4 were all 0.94 (95%CI 0.92-0.96). No significant publication biases were not observed for VI-RADS 3 (P = 0.74) and 4 (P = 0.57).
CONCLUSION: The VI-RADS reveals a good diagnostic performance for predicting muscle invasive in bladder cancer, which also has good clinical utilities and applicability. And VI-RADS 3 and 4 as cutoff values provide similar overall diagnostic and could be selectively applied individually. Prospective studies with a large scale are further required to validate the accuracy of the VI-RADS score.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bladder cancer; Magnetic resonance imaging; Meta-analysis; Muscle invasion; Vesical imaging-reporting and data system

Mesh:

Year:  2022        PMID: 35181798     DOI: 10.1007/s00261-022-03449-w

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  36 in total

Review 1.  Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.

Authors:  Johannes B Reitsma; Afina S Glas; Anne W S Rutjes; Rob J P M Scholten; Patrick M Bossuyt; Aeilko H Zwinderman
Journal:  J Clin Epidemiol       Date:  2005-10       Impact factor: 6.437

2.  Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.

Authors:  Yoshiko Ueno; Mitsuru Takeuchi; Tsutomu Tamada; Keitaro Sofue; Satoru Takahashi; Yuki Kamishima; Nobuyuki Hinata; Kenichi Harada; Masato Fujisawa; Takamichi Murakami
Journal:  Eur Urol       Date:  2019-03-26       Impact factor: 20.096

3.  Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience.

Authors:  Ahmed El-Assmy; Mohamed E Abou-El-Ghar; Huda F Refaie; Ahmed Mosbah; Tarek El-Diasty
Journal:  BJU Int       Date:  2012-07-03       Impact factor: 5.588

4.  Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Authors:  Sungmin Woo; Valeria Panebianco; Yoshifumi Narumi; Francesco Del Giudice; Valdair F Muglia; Mitsuru Takeuchi; Soleen Ghafoor; Bernard H Bochner; Alvin C Goh; Hedvig Hricak; James W F Catto; Hebert Alberto Vargas
Journal:  Eur Urol Oncol       Date:  2020-03-19

5.  Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade.

Authors:  Mitsuru Takeuchi; Shigeru Sasaki; Masato Ito; Shinsuke Okada; Satoru Takahashi; Tatsuya Kawai; Kaori Suzuki; Hidekazu Oshima; Masaki Hara; Yuta Shibamoto
Journal:  Radiology       Date:  2009-04       Impact factor: 11.105

6.  Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.

Authors:  Paramananthan Mariappan; Alexandra Zachou; Kenneth M Grigor
Journal:  Eur Urol       Date:  2009-06-06       Impact factor: 20.096

7.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

Review 8.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Authors:  Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup
Journal:  Eur Urol       Date:  2019-08-20       Impact factor: 20.096

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

Review 10.  Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Authors:  Valeria Panebianco; Yoshifumi Narumi; Ersan Altun; Bernard H Bochner; Jason A Efstathiou; Shaista Hafeez; Robert Huddart; Steve Kennish; Seth Lerner; Rodolfo Montironi; Valdair F Muglia; Georg Salomon; Stephen Thomas; Hebert Alberto Vargas; J Alfred Witjes; Mitsuru Takeuchi; Jelle Barentsz; James W F Catto
Journal:  Eur Urol       Date:  2018-05-10       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.